Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.

Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Deeg HJ, Devine SM, Fernandez HF, Giralt S, Hamadani M, Howard A, Maziarz RT, Porter DL, Scott BL, Warlick ED, Pasquini MC, Horwitz ME.

J Clin Oncol. 2019 Dec 20:JCO1903011. doi: 10.1200/JCO.19.03011. [Epub ahead of print]

PMID:
31860405
2.

Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia.

Ghannam J, Dillon LW, Hourigan CS.

Br J Haematol. 2020 Jan;188(1):77-85. doi: 10.1111/bjh.16362. Epub 2019 Dec 5. Review.

PMID:
31804716
3.

Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response.

Wong HY, Sung AD, Lindblad KE, Sheela S, Roloff GW, Rizzieri D, Goswami M, Mulé MP, Ramos NR, Tang J, Thompson J, DeStefano CB, Romero K, Dillon LW, Kim DY, Lai C, Hourigan CS.

Front Oncol. 2019 Jan 15;8:669. doi: 10.3389/fonc.2018.00669. eCollection 2018.

4.

Pathogenic TERT promoter variants in telomere diseases.

Gutierrez-Rodrigues F, Donaires FS, Pinto A, Vicente A, Dillon LW, Clé DV, Santana BA, Pirooznia M, Ibanez MDPF, Townsley DM, Kajigaya S, Hourigan CS, Cooper JN, Calado RT, Young NS.

Genet Med. 2019 Jul;21(7):1594-1602. doi: 10.1038/s41436-018-0385-x. Epub 2018 Dec 7.

5.

Human bone marrow assessment by single-cell RNA sequencing, mass cytometry, and flow cytometry.

Oetjen KA, Lindblad KE, Goswami M, Gui G, Dagur PK, Lai C, Dillon LW, McCoy JP, Hourigan CS.

JCI Insight. 2018 Dec 6;3(23). pii: 124928. doi: 10.1172/jci.insight.124928.

6.

Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia.

Dillon LW, Hayati S, Roloff GW, Tunc I, Pirooznia M, Mitrofanova A, Hourigan CS.

Haematologica. 2019 Feb;104(2):297-304. doi: 10.3324/haematol.2018.203133. Epub 2018 Aug 31.

7.

Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia.

Roloff GW, Lai C, Hourigan CS, Dillon LW.

J Clin Med. 2017 Sep 19;6(9). pii: E87. doi: 10.3390/jcm6090087. Review.

8.

Normal and Cancerous Tissues Release Extrachromosomal Circular DNA (eccDNA) into the Circulation.

Kumar P, Dillon LW, Shibata Y, Jazaeri AA, Jones DR, Dutta A.

Mol Cancer Res. 2017 Sep;15(9):1197-1205. doi: 10.1158/1541-7786.MCR-17-0095. Epub 2017 May 26.

9.

DNA fragile site breakage as a measure of chemical exposure and predictor of individual susceptibility to form oncogenic rearrangements.

Lehman CE, Dillon LW, Nikiforov YE, Wang YH.

Carcinogenesis. 2017 Mar 1;38(3):293-301. doi: 10.1093/carcin/bgw210.

10.

Production of Extrachromosomal MicroDNAs Is Linked to Mismatch Repair Pathways and Transcriptional Activity.

Dillon LW, Kumar P, Shibata Y, Wang YH, Willcox S, Griffith JD, Pommier Y, Takeda S, Dutta A.

Cell Rep. 2015 Jun 23;11(11):1749-59. doi: 10.1016/j.celrep.2015.05.020. Epub 2015 Jun 4.

11.

Human Primpol1: a novel guardian of stalled replication forks.

Im JS, Lee KY, Dillon LW, Dutta A.

EMBO Rep. 2013 Dec;14(12):1032-3. doi: 10.1038/embor.2013.171. Epub 2013 Nov 5. No abstract available.

12.

DNA topoisomerases participate in fragility of the oncogene RET.

Dillon LW, Pierce LC, Lehman CE, Nikiforov YE, Wang YH.

PLoS One. 2013 Sep 11;8(9):e75741. doi: 10.1371/journal.pone.0075741. eCollection 2013.

13.

Role of DNA secondary structures in fragile site breakage along human chromosome 10.

Dillon LW, Pierce LC, Ng MC, Wang YH.

Hum Mol Genet. 2013 Apr 1;22(7):1443-56. doi: 10.1093/hmg/dds561. Epub 2013 Jan 7.

14.

The role of fragile sites in sporadic papillary thyroid carcinoma.

Dillon LW, Lehman CE, Wang YH.

J Thyroid Res. 2012;2012:927683. doi: 10.1155/2012/927683. Epub 2012 Jun 11.

15.

Outcomes of a 12-month web-based intervention for overweight and obese men.

Patrick K, Calfas KJ, Norman GJ, Rosenberg D, Zabinski MF, Sallis JF, Rock CL, Dillon LW.

Ann Behav Med. 2011 Dec;42(3):391-401. doi: 10.1007/s12160-011-9296-7.

PMID:
21822750
16.

DNA instability at chromosomal fragile sites in cancer.

Dillon LW, Burrow AA, Wang YH.

Curr Genomics. 2010 Aug;11(5):326-37. doi: 10.2174/138920210791616699.

17.

DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells.

Gandhi M, Dillon LW, Pramanik S, Nikiforov YE, Wang YH.

Oncogene. 2010 Apr 15;29(15):2272-80. doi: 10.1038/onc.2009.502. Epub 2010 Jan 25.

Supplemental Content

Loading ...
Support Center